Research Library

Despite a revised institutional approach to fighting corruption, Mexico continues to face issues related to systemic corruption in the public and private arenas, writes nonresident scholar Stephen D. Morris.

In recent years public opinion surveys have found that a consistent and increasing percentage of Texans support marijuana reform, but this support has not translated into policy change. The authors explain why it should.

By providing regulated and safe access to medical cannabis to people with demonstrated need, the Texas Legislature can provide justified relief, help reduce the opioid epidemic, and save Texas millions of dollars, write the authors.

If the United States-Mexico-Canada Agreement (USMCA) is approved, this modified and modernized version of NAFTA will govern most economic relationships in North America. David A. Gantz, the Will Clayton Fellow in Trade and International Economics, reviews the USMCA and discusses its positive and negative elements.

State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices — but they arguably make safety and efficacy secondary to speedy access.

The core strategies of the U.S. War on Drugs are eradication, interdiction and incarceration. After a 40-year and trillion-dollar effort, illicit drugs remain available to meet a remarkably stable demand. Drawing on decades of government-gathered and publicly available data, William Martin, director of the Drug Policy Program, and contributing expert Jerry Epstein contend that U.S. drug policy is premised on incorrect assumptions, aims at the wrong targets and can never succeed. But because these data run counter to a century of anti-drug propaganda, they play only a small role in public policy, mass-media presentation and popular perception. In this policy report, Martin and Epstein call for a reexamination of the data and sweeping revision of existing strategies. They urge formation of a politically independent national scientific commission, its members chosen by the National Academy of Sciences, in consultation with the NIH and the Department of Health and Human Services, to facilitate open examination and honest consideration of alternatives to current failed or flawed policies.

Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.